Tyra Biosciences’ (TYRA) “Buy” Rating Reiterated at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 207.06% from the stock’s current price.

A number of other analysts have also issued reports on TYRA. Wedbush reissued an “outperform” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Friday. UBS Group began coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences presently has an average rating of “Buy” and a consensus price target of $30.83.

Tyra Biosciences Stock Up 1.1 %

Shares of Tyra Biosciences stock opened at $9.77 on Monday. The firm has a market cap of $494.39 million, a PE ratio of -6.07 and a beta of 1.09. Tyra Biosciences has a 52 week low of $9.49 and a 52 week high of $29.60. The business’s fifty day simple moving average is $12.46 and its 200-day simple moving average is $16.30.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. As a group, equities analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 3,993 shares of Tyra Biosciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the sale, the director now directly owns 3,707,420 shares of the company’s stock, valued at approximately $60,653,391.20. The trade was a 0.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Tyra Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of TYRA. KLP Kapitalforvaltning AS purchased a new position in shares of Tyra Biosciences in the 4th quarter valued at about $31,000. US Bancorp DE acquired a new position in Tyra Biosciences in the fourth quarter valued at approximately $50,000. BNP Paribas Financial Markets purchased a new position in Tyra Biosciences in the fourth quarter valued at approximately $60,000. Aquatic Capital Management LLC acquired a new stake in Tyra Biosciences during the fourth quarter worth approximately $64,000. Finally, Wells Fargo & Company MN lifted its position in shares of Tyra Biosciences by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after buying an additional 3,236 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.